KRAS mutations are present in nearly 95% of PDAC tumors and co‐present with TP53 mutation in approximately 70% of PDAC tumors.[1] PDAC has approximately 10% 5‐year relative survival rates and is the third leading cause of cancer‐related deaths in the US.[2] The dismal prognosis pertains to few early diagnostic tools, chemoresistance, and high incidence of comorbidities including cachexia.[3] Therefore, more efforts are needed towards improving PDAC prognosis by identifying prognostic factors for PDAC and their underlying mechanisms.[4]. This evidence concerns the gene KRAS and cancer.